ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

PEG-INTRON
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

PEG-INTRON Rx

Generic Name and Formulations:
Peginterferon alfa-2b (polyethylene glycol/recombinant alfa interferon conjugate) 100mcg/mL, 160mcg/mL, 240mcg/mL, 300mcg/mL; per single-use pen or per vial after reconstitution; pwd for SC inj after reconstitution/dilution.

Company:
Merck & Co., Inc.

Therapeutic Use:

Indications for PEG-INTRON:

Chronic hepatitis C with compensated liver disease.

Adult:

Give SC once weekly (same day each week). ≥18yrs: Monotherapy: initially 1mcg/kg/week. Treat for 1 year; consider discontinuing if inadequate response after 6 months. Combination with ribavirin: 1.5mcg/kg/week. Alpha-naive patients: Genotype 1: treat for 48 weeks. Discontinue therapy if treatment Week 12 HCV-RNA drops <2 log10 or at 24 weeks if HCV-RNA are detectable. Genotype 2/3: treat for 24 weeks. Prior treatment failure: add HCV NS3/4A protease inhibitor (unless contraindicated); treat for 48 weeks. Consider discontinuing if patient fails to achieve undetectable HCV-RNA at Week 12 or 24. Reduce dose if serious adverse reaction develops (discontinue if persists). Neutropenia, thrombocytopenia, depression: see full labeling. Renal impairment: CrCl 30–50mL/min: reduce dose by 25%; CrCl 10–29mL/min, hemodialysis: reduce dose by 50%.

Children:

<3yrs: not established. Give by SC inj. Combination w. ribavirin: ≥3yrs: 60mcg/m2/week. Genotype 1: Discontinue therapy at 12 weeks if treatment Week 12 HCV-RNA drops <2 log10 compared to pretreatment or at 24 weeks if HCV-RNA are detectable. Genotype 2/3: treat for 24 weeks. Reduce dose if serious adverse reaction develops (discontinue if persists). Neutropenia, thrombocytopenia, depression: see full labeling. Renal impairment: CrCl 30–50mL/min: reduce dose by 25%; CrCl 10–29mL/min, hemodialysis: reduce dose by 50%.

Contraindications:

Hepatic decompensation (Child-Pugh score >6 [Class B and C]) before or during treatment. Autoimmune hepatitis.

Warnings/Precautions:

May cause or exacerbate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, or infectious disorders: monitor closely, discontinue if they worsen. Severe psychiatric disorders (esp. depression). Cardiovascular or pulmonary disease. Severe myelosuppression, colitis, pancreatitis: discontinue if occurs. Uncontrolled thyroid abnormalities. Diabetes. Autoimmune disorders. Coagulation disorders. Maintain adequate hydration. Monitor blood, thyroid, visual and liver function before and during therapy; EKG in cardiovascular disease. Psoriasis. Renal dysfunction (CrCl <50mL/min). Transplant recipients. Hepatitis C virus with HIV or HBV coinfection. Elderly. Debilitated. Pregnancy (Cat.C); use adequate contraception. Nursing mothers: not recommended.

Interactions:

Caution with myelosuppressives, and drugs that can exacerbate depression. May potentiate methadone (monitor). Caution with drugs metabolized by CYP2C8/9 (eg, warfarin, phenytoin), or CYP2D6 (eg, flecainide). Concomitant nucleoside analogues: closely monitor for toxicities; discontinue interferon, ribavirin, or both with worsening toxicities (see full labeling).

Adverse Reactions:

Flu-like symptoms (fever, headache, myalgia, fatigue); hepatic, hematologic, respiratory, skin, genitourinary system, CNS, cardiovascular, endocrine (esp. thyroid), dental/periodontal, or visual disorders, injection site reactions, anxiety/emotional lability/irritability, nausea; hemorrhagic colitis, hypertriglyceridemia, pancreatitis, antibody formation, infections; Others (see full labeling). Children: weight loss, growth inhibition, pyrexia, headache, vomiting, neutropenia, anorexia, injection site erythema.

Note:

Note: See Rebetol entry for more information on ribavirin.

How Supplied:

Pwd in vials (0.5mL)—1 (w. diluent, supplies); Redipen (0.5mL)—1, 4 (w. supplies)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs